Interim data from a National Cancer Institute Center for Cancer Research study show demonstrated immune reactions in patients with breast cancer following immunotherapy with their own tumor-infiltrating lymphocytes (TIL).
Targeted immunotherapy that utilizes a patient’s own tumor-infiltrating lymphocytes (TIL) may be added to the treatment armamentarium for individuals with metastatic breast cancer with repeated treatment failures, according to a new Journal of Clinical Oncology study.
In particular, patients with hormone receptor (HR)-positive cancers may benefit from the personalized treatment, as “it’s popular dogma that HR-positive breast cancers are not capable of provoking an immune response and are not susceptible to immunotherapy,” said lead author Steven A. Rosenberg, MD, PhD, chief of the Surgery Branch in National Cancer Institute's Center for Cancer Research, in a statement announcing the findings.
At present, the effectiveness of TIL against breast cancers is not 100% solidified because these types of cancers have fewer mutation-produced neoantigens, or surface proteins, that TIL recognize and target on tumors, the statement read.
Forty-two patients (median age, 46 [range 35-67] years) with refractory metastatic breast cancer were recruited for the ongoing phase 2 study. Mutations from their tumor samples were analyzed via whole-genome sequencing, after which TIL were isolated and tested against the mutations’ neoantigens. Most had stage II to IV disease, 43% of tumors were HR positive/ human epidermal growth factor receptor 2 negative, and 38% had triple-negative breast cancer. Median prior treatment consisted of 4 (range, 1-10) lines of therapy.
The primary end point was objective response measured using Response Evaluation Criteria in Solid Tumors 1.0.
A median 112 (range, 6-563) nonsynonymous mutations were identified overall per patient following surgical tumor resection; this was not linked to clinical receptor status, tumor site, or presence/or absence of known deleterious BRCA germline variants. In addition, just over two-thirds of the cohort (67%; 28 patients) had at least 1 mutation recognized by TIL; among this group, there were a median 3 (range, 1-11) neoantigens per patient.
The full study cohort had undergone surgical tumor resection, with the tissue used to isolate TIL cultures, identify exomic nonsynonymous mutations, and screened for neoantigen reactivity.
Among the smaller group of 28 patients, 13 were identified as having robust reactivity. Six were identified as candidates for adoptive cell transfer (ACT) of their autologous TIL following nonmyelobaltive lymphodepleting chemotherapy consisting of 60-mg/kg daily cyclophosphamide on days –7 and –6 and 25-mg/m2 daily fludarabine from day –7 through day –3. All also received a short course of treatment with pembrolizumab 2 days before ACT, which continued with 3 doses delivered every 3 weeks when appropriate.
“The total number of infused cells ranged from 3.06e10 to 1.04e11 (median, 6.00e10) per patient and were predominantly CD4+ T cells (CD4+ median, 56% [range, 46%-97%]; CD8+ median, 37.5% [range, 2%-52%]),” the authors wrote. “The frequency of the neoantigen-reactive T cells of the infused TIL ranged from 10.4% to 75.2%, as estimated by TCR sequencing.”
Three patients had an objective tumor response: one patient with metastatic liver, lymph node, and mediastinum tumors has ongoing complete tumor regression and 2 had partial responses of 6 and 10 months.
When discussing the strength of their findings, the authors highlighted their use of ex vivo functional assays for precise identification and validation of neoantigens instead of predictive algorithms to characterize TIL and immunogenicity. Still, they recognize that these are interim results and that the patient cohort was too small “to address potential correlates of response, including the number and abundance of neoantigen reactivities.”
Future steps will include additional patient recruitment to continue to explore this targeted approach among patients with metastatic breast cancer.
“Completion of the cohort is critical to evaluate the efficacy, as well as the challenges, of this highly personalized treatment against metastatic breast cancer,” they concluded.
Reference
Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase 2 pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol. Published online February 1, 2022. doi:10.1200/JCO.21.02170
Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women
May 13th 2024A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
The Disproportionate Impact of the Pandemic on Health Care Disparities and Cancer
February 22nd 2022On this episode of Managed Care Cast, we discuss how already wide health care inequities in cancer are becoming much worse because of the COVID-19 pandemic, with guest Monica Soni, MD, associate chief medical officer at New Century Health.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More